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Unlike  linear  peptides,  analysis  of cyclic  peptides  containing  disulﬁde  bonds  is not straightforward  and
demands  indirect  methods  to  achieve  a  rigorous  proof  of structure.  Three  peptides  that  belong  to  this
category,  p-Cl-Phe-DPDPE,  DPDPE,  and CTOP,  were  analyzed  and the  results  are  presented  in this  paper.
The  great  potential  of  two dimensional  NMR  and  ESI  tandem  mass  spectrometry  was  harnessed  during
the  course  of peptide  characterizations.  A  new  RP-HPLC  method  for  the  analysis  of  triﬂuoroacetic  acid  iseywords:
pioid peptides
riﬂuoroacetic acid
P-HPLC
andem mass spectrometry
also  presented.  It is robust,  simple,  and  efﬁcient  compared  to  the  currently  available  methods.
©  2015  Published  by  Elsevier  B.V.wo-dimensional NMR
. Introduction
Developments of opioid peptides as promising nonaddicting
nalgesics [1–3] began in 1770s when the discovery of opi-
te receptors led to the discovery of two endogenous opioid
eptides Met5-Enkephalin (H-Tyr-Gly-Gly-Phe-Met-OH) and Leu5-
nkephalin (H-Tyr-Gly-Gly-Phe-Leu-OH). Given the multitude of
eported side effects of currently available analgesics, a search
or nonaddicting analgesics based on endogenous opioid pep-
ide ligands is a timely endeavor. In addition to the nonaddicting
roperties, other features such as improved biological activity,
ioavailability, and reduced toxicity drew attention during these
tudies.
With the above objectives, a strategy that has been employed
n opioid peptide research includes replacing natural amino
cids of endogenous peptides with modiﬁed amino acids and
eptidomimetic ligands [4–10]. In comparison to those endoge-
ous ligands that are linear, cyclization was designed in this
lass of synthetic peptides in order to reduce conformational
reedom as it enhances the receptor selectivity along with
ther advantages [10]. Cyclic opioid peptides such as DPDPE
Tyr-c(D-Pen-Gly-Phe-D-Pen); D-Pen (2,5)-enkephalin] and p-Cl-
he-DPDPE [Tyr-c(D-Pen-Gly-p-Cl-Phe-D-Pen)] in which the 2-
nd 5- amino acid residues of enkephalin have been replaced
y a sterically constrained derivative D-Pen (penicillamine; ,
∗ Corresponding author. Tel.: +1 650 859 3682;fax: +1 650 859 4291.
E-mail address: kanthi.hettiarachchi@gmail.com (K. Hettiarachchi).
1 19 Lorelei lane, Menlo Park, CA 94025. Tel.: +1 650 521 4631.
ttp://dx.doi.org/10.1016/j.jpba.2015.01.009
731-7085/© 2015 Published by Elsevier B.V. -dimethylcysteine) belong to this category. Both peptides
contain a disulﬁde bond via the two D-Pen derivatives and
were proven to be potent, stable and possessing  receptor
selectivity. CTOP [D-Phe-c(Cys-Tyr-D-Trp-Orn-Thr-Pen)Thr-NH2;
[Cys(2),Tyr(3),Orn(5),Pen(7)amide] is a synthetic opioid peptide
that contains a disulﬁde bond via Cysteine and D-Pen moieties, also
proven to be potent, but showing  receptor selectivity.
During the synthesis of a cyclic peptide that contains a disulﬁde
bond, the linear form is usually assembled ﬁrst. The oxidation of the
two thiols to form the disulﬁde bridge is performed towards the end
of the synthetic plan. Once such a cyclic peptide is synthesized, a
variety of analytical challenges to prove its structure are presented.
Unlike a linear peptide, achieving complete amino acid information
for such cyclic compounds via conventional amino acid analysis will
not be feasible and one may  have to seek alternative means, such
as mass spectrometry (MS).
Also, conventional Edman degradation is not amenable to the
sequencing of cyclic peptides. Here again, MS  is required to obtain
amino acid sequencing information. But in this case, perhaps only a
few sequencing fragments may  be evident, though observing sufﬁ-
cient fragments to prove the sequence is not guaranteed. Under the
circumstance of not observing sequencing fragments, the question
arises on how the structure can be veriﬁed. A ready answer could
be the advanced two-dimensional NMR  techniques, such as cor-
relation spectroscopy (COSY) and nuclear overhauser effect spec-
troscopy (NOESY) that may  offer valuable structural information.Furthermore, if a cyclic peptide such as DPDPE that contains
a disulﬁde bond is prepared from its linear precursor, the two
peptides differ in their molecular masses by only 2 mass units
(daltons, Da). Under such circumstances, an important question
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rises: How would one ascertain whether there is any contam-
nation by the linear precursor? Here, the subject peptide and
he presumed impurity both contain the same amino acid skele-
on. The only difference being that one has a disulﬁde bond
hereas the other is a dithiol with the two additional pro-
ons.
Under a separation technique such as HPLC, the precursor may
e represented as an impurity peak. However, observation of a
ingle major peak, say in an extreme case with no observable impu-
ities, is not an unambiguous answer because of the possibility that
he linear precursor may  not be retained under those particular sep-
ration conditions or it might get co-eluted with the major peak.
ncorporation of other HPLC methods and/or other analytical meth-
ds such as CE with different separation principles in the analytical
rotocol seems to be logical and can be effective [11,12]. Also, a
omparison with the linear precursor of the peptide is highly rele-
ant. A simple and fast way to obtain this is by reducing the disulﬁde
ond of the cyclic peptide. This reduction can be easily achieved by
sing a reducing agent such as dithiothreitol (DTT). This reagent
as been used extensively, particularly on the studies of peptide
nd protein chemistry [13–17].
The work presented here covers the methods and results we
btained during analysis and structural veriﬁcation of three cyclic
pioid peptides p-Cl-Phe-DPDPE, DPDPE, and CTOP. Each peptide
ontains a disulﬁde bond, the ﬁrst two via two D-Pen molecules and
he latter via a cysteine and a D-Pen molecule. They were all fully
haracterized, identity veriﬁed, and the purity and potency were
etermined. As discussed below, all peptides needed indirect meth-
ds for their characterization. Our experimental protocols included
TT reduction of the cyclic peptide followed by LC-MS. For p-Cl-
he-DPDPE and DPDPE, LC-MS was coupled with fraction collection
nd electrospray ionization tandem MS  (MS-MS) as unequivocal
roof of structure.
Triﬂuoroacetic acid (TFA) is a reagent that has many appli-
ations, particularly in peptide/protein chemistry, including their
ynthesis, puriﬁcation and analysis. Sometimes, in addition to TFA,
he puriﬁed peptide samples contain acetic acid (AA) as well and
herefore, simultaneous determination of these acids is desirable
nd has been achieved by RP-HPLC [18] and CE with indirect UV
etection [19].
Quantiﬁcation of TFA contained in each sample was performed
sing an efﬁcient and robust HPLC method developed during our
tudies. Development of this RP-HPLC method is also reported
n this paper. The method is efﬁcient, each HPLC run taking
 min. It is simple and can be easily integrated into any analytical
aboratory that has an HPLC system. As illustrated here, the method
s applicable for the analysis of both TFA and AA.
Fig. 1. RP-HPLC chromatogram of p-Cl-Phe-DPDPE. Inset is the Biomedical Analysis 109 (2015) 112–120 113
Additional information is provided as supplementary data.
2. Experimental
2.1. Reagents and materials
The reagents used in our experiments were acetonitrile,
HPLC-grade and tris from Mallinckrodt, (Paris, Kentucky, USA), tri-
ﬂuoroacetic acid, >99.0% (GC), DL-dithiothreitol, DMSO-d6, and D2O
from Sigma-Aldrich (St. Louis, Missouri, USA). The mobile phases
were prepared in Milli-Q water.
All peptide samples were supplied by the PolyPeptide Labora-
tories, San Diego, CA.
2.2. Instrumentation and methods
2.2.1. RP-HPLC for peptide purity determination
Analysis was performed on an Agilent 1100 HPLC system with
diode-array detection (DAD). 10 L of each sample (1 mg/mL  in
water) was injected on a Phenomenex Gemini-NX C18 column,
5 m,  110 A˚, 250 × 4.6 mm.  This column was purchased from
Phenomenex (Torrance, California, USA). The detection wavelength
was set at 215 nm.  Mobile phase A was 0.05% TFA in water and
mobile phase B was 0.05% TFA in acetonitrile. The separation was
obtained at a ﬂow rate of 1 mL/min with a gradient program that
allowed for a 20 min  step that raised eluent B from 20 to 55%. Equi-
libration at 20% B was  then performed for 10 min for a total analysis
time of 30 min.
2.2.2. RP-HPLC for TFA and AA analysis
Analysis was performed on an Agilent 1100 HPLC system with
DAD. 20 L of each sample (1 mg/mL  in water) was injected
on a Phenomenex Synergi Hydro-RP C18 column, 4 m, 80 A˚,
150 × 4.6 mm.  This column was  purchased from Phenomenex
(Torrance, California, USA). The detection wavelength was set
at 215 nm.  Mobile phase A was  acetonitrile and mobile phase
B was  20 mM KH2PO4 adjusted to pH 2.5. The separation
was obtained at a ﬂow rate of 1 mL/min with a run time of
5 min.
2.2.3. LC-MS
Analysis was performed on a Thermo-Scientiﬁc LCQ Fleet MS
and Finnigan Surveyor HPLC system. 5 L of each sample (1 mg/mL
in water) was injected on a Phenomenex Gemini-NX C18 column,
5 m,  110 A˚, 250 × 4.6 mm.  This column was purchased from Phe-
nomenex (Torrance, California, USA). The detection wavelength
was set at 215 nm.  Mobile phase A was 0.1% TFA in water and mobile
 expanded baseline showing the minor/trace impurities.
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hase B was 0.1% TFA in acetonitrile. The separation was obtained
t a ﬂow rate of 0.5 mL/min with a gradient program that allowed
or a 7 min  step that raised eluent B from 35 to 50%. Eluent B was
eld at 50% for 6 min. Equilibration at 35% B was then performed
or 10 min  for a total analysis time of 23 min.
.2.4. NMR
The instrument used to perform NMR  analysis was a Varian Mer-
ury 400. 11.7 mg  sample was dissolved in 0.5 mL  DMSO-d6 with
wo drops of D2O.
. Results and discussion
.1. Analysis of p-Cl-Phe-DPDPE
.1.1. RP-HPLC experiments
When we analyzed the peptide sample by RP-HPLC, the result
ndicated a high degree of purity, 99.5 ± 0.1%, n = 3 (Fig. 1), based on
he assumption that all components have equal UV absorptions at
he detection wavelength. Furthermore, it has to be recognized that
he level of purity is dependent on the speciﬁc analytical methods
sed. The HPLC purity result was in agreement with the manufac-
urer’s data.
In addition to HPLC, CE experiments were also performed. They
ndicated a purity result of 99.8 ± 0.1% and are in close agreement
ith the HPLC result.
.1.2. Determination of TFA and acetic acid
TFA was present in the sample as the counter ion and also
eeded quantiﬁcation. This was achieved using a polar endcapped
18 column that provides extreme hydrophobic and slight polar
electivity.
Five TFA standards ranging from 10 g/mL to 500 g/mL
ere prepared and chromatographed to construct a standard
urve. The equation obtained from the standard curve was
 = 0.3387x − 1.3203, with R2 = 1.
Based on the results of three test samples, the peptide contains
0.18 ± 0.12% TFA.
Although the three particular peptides, p-Cl-Phe-DPDPE,
PDPE, and CTOP that are discussed in this paper do not contain
ny acetic acid, we have occasionally encountered some peptides
ontaining both TFA and AA. Therefore, we extended the method
or the detection of AA as well. As claimed by Phenomenex, the
ynergi Hydro-RP column manufacturers, this method is capable
f resolving AA from eight other acids present in a mixture. Our0 L/mL water) and AA (250 L/mL water).
observation is that the method is capable of detecting AA and is
well separated from TFA as is illustrated in Fig. 2.
Elemental nitrogen data indicated a peptide content of
80.3 ± 0.1%, n = 2 and Karl Fischer water determination yielded a
result of 5.5 ± 0.2%, n = 3 for the water content.
On the material balance, considering the data gathered so far, a
peptide content of 80.3%, water content of 5.5%, and TFA content of
10.2% yield a total 96%. Impurities may  account for the remainder.
Underlying method errors in each technique also become a con-
tributing factor in the ﬁnal purity result. However, our efforts were
next directed towards proving the structure of the peptide and ver-
ifying whether there is any contamination by the linear precursor
peptide.
3.1.3. MS, AAA and AASA
Mass spectrometry revealed an (M + H)+ ion at 679.99 and an
alkali ion, the sodium adduct (M + Na)+ at 702.05 revealing the
expected average molecular mass 680.2 of the peptide, but the MS
spectrum was devoid of any sequencing fragments to prove the
structure.
Usually, the information on the amino acid composition and
their sequence are obtained by conventional amino acid analysis
(AAA) and Edman degradation methods. But for p-Cl-Phe-DPDPE,
AAA information was incomplete and amino acid sequence analysis
(AASA) was not amenable because of the cyclic structure.
Thus, as evidenced above, despite the fact that the subject
peptide can be considered as a small molecule, its cyclic nature
prevented the use of direct conventional techniques MS,  AAA, and
AASA for its analysis.
3.1.4. NMR of p-Cl-Phe-DPDPE
In the absence of sequencing fragments in MS,  and inability to
obtain any AAA and AASA information, we  were prompted to use
NMR for structural scrutiny.
The 1H-NMR spectrum of p-Cl-Phe-DPDPE is shown in Fig. 3.
The NMR  chemical shifts and the respective proton assignments
are presented in Table 1.
1H- NMR  spectrum of p-Cl-Phe-DPDPE showed twelve methines
(CH) including eight oleﬁnic protons at ıH = 6.66, 7.03, 7.20 and
7.26 ppm, and four methyl (CH3) singlets at ıH = 0.86, 1.22, 1.26
and 1.27 ppm. Several multiplets observed between ıH 2.75 ppm
and 4.23 ppm are attributed to three methylenes (CH2).The 1H–1H COSY spectrum, shown in Fig. 4, revealed six proton-
bearing spin coupling units and are illustrated with bold bonds as
shown in Fig. 4a. These six units are H-7/H2-8, H-10/H-11, H-13/H-
14, H-23/H2-24, H-26/H-27, and H-29/H-30. The presence of two
M. Johnson et al. / Journal of Pharmaceutical and Biomedical Analysis 109 (2015) 112–120 115
Fig. 3. 1H-NMR spectrum of p-Cl-Phe-DPDPE.
Fig. 4. 1H–1H COSY spectrum of p-Cl-Phe-DPDPE and the main 1H–1H COSY and NOE correlations of p-Cl-Phe-DPDPE.
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(Fig. 5. NOESY spec
isubstituted benzene rings(AAB´Bs´ystem) was easily recognized by
he 1H resonances{[ıH 7.26, (2H, d J = 8.4 Hz, H-11 and H-13), ıH
.20, (2H, d J = 8.8 Hz, H-10 and H-14)] and [ıH 7.03, (2H, d J = 8.8 Hz,
-26 and H-30), ıH 6.66, (2H, d J = 8.8 Hz, H-27 and H-29)]}. 1H–1H
OSY data also exhibit two doublets (ıH 3.21/4.23) from AB spin
ystem with large geminal coupling constants (J = 14.8 Hz), which
ssigned to the isolated methylenes H2-16. The connection of C-
4/C-25 and C-8/C-9 was achieved by the NOE correlations from
2-24 to H-26/H-30 and from H2-8 to H-10/H-14. The NOE corre-
ations from H-18 to CH3-20/CH3-21 and from H-2 to CH3-4/CH3-5
stablished the connection of C-2/C-3 and C-18/C-19, and also
laced CH3-20/CH3-2 and CH3-4/CH3-5 on C-19 and C-3, respec-
ively. In conclusion, the NOE correlations of CH3-4 and CH3-20
ndicated that p-Cl-Phe-DPDPE was a cyclic peptide containing
 disulﬁde bond between C-3 and C-19. The NOESY spectrum is
hown in Fig. 5.
.1.5. DTT reduction
As shown above, the peptide structure was proven by NMR  tech-
iques 1H-NMR, 1H–1H COSY and NOESY.
However, the question of whether there is any contamination
y the linear precursor still remains. If the sample is contaminated
ith its linear precursor, we needed to address the following three
otential scenarios:1) Co-elution with the major peak in HPLC
2) The linear precursor’s presence as a minor peak
3) The linear precursor not eluting under the HPLC conditions
being used.f p-Cl-Phe-DPDPE.
When the structures of the two  compounds are considered,
the precursor molecule is a linear peptide that contains two thiol
groups whereas the subject compound is a cyclic peptide with a
disulﬁde bond. With such a structural difference between the two
compounds, one would expect them to resolve during HPLC. On an
RP- HPLC column, the linear peptide should be more retained due to
the polarity imparted by the two  thiol groups. It was  apparent that
additional experiments including the linear precursor were needed,
so we attempted to obtain this by reducing the cyclic peptide. Here,
the cyclic peptide was  opened up at the disulﬁde bond using DTT
in the presence of tris buffer. The peptide (2 mg)  was  dissolved
in 1 mL  50 mM tris buffer. DTT was  added to the peptide solu-
tion (in excess, 1.5 mg)  and kept stirring. The LC-MS experiments
discussed below were performed after the solutions were stirred
overnight.
Fig. 6 shows an HPLC proﬁle of the DTT-treated sample solu-
tion. There were two early eluting peaks which were shown to
be DTT artifacts, a major peak that eluted around the similar time
(10.7 min) as the untreated sample (Fig. 1) and a new minor peak
at 13.8 min, presumably the linear form. We  endeavored to prove
that this peak was the linear form of the peptide using LC-MS.
3.1.6. LC-MS
In addition to HPLC experiments discussed above, treatment of
the sample with DTT was  followed by LC-MS analysis. During the
method transfer, the conditions used for HPLC experiments needed
modiﬁcation to suit the LC-MS format.
The HPLC chromatogram after DTT treatment under LC-MS con-
ditions is shown in Fig. 7. The ﬁrst peak at 6.48 min was  shown to be
a DTT artifact and due to the adjustment of the method, the other
M. Johnson et al. / Journal of Pharmaceutical and Biomedical Analysis 109 (2015) 112–120 117
Table  1
The 1chemical shifts and the respective proton assignments.
Chemical Shift (ppm) Pattern J (Hz) Relative
Intensity
Proton Assignment
7.26 d (8.4) 2 11, 13
7.20 d (8.8) 2 10, 14
7.03 d (8.8) 2 26, 30
6.66 d (8.8) 2 27, 29
4.32 s 1 2
4.26 dd (4.4, 10.4) 1 7
4.25 s 1 18
4.23 d (14.8) 1 16b
4.20 t (7.6) 1 23
3.21 d (14.8) 1 16a
3.02 dd (4.4, 14.0) 1 8b
2.89 m 2 24
2.78 dd (10.4, 14.0) 1 8a
t
H
f
b
f
D
6
o
i
1
t1.27, 1.22 s 6 20, 21
1.26, 0.86 s 6 4, 5
wo peaks eluted a little earlier than what was observed under the
PLC conditions.
However, as seen in Figs. 6 and 7, disregarding the DTT arti-
acts, the proportions of the other two peaks are different. This is
ecause of the time dependence of the DTT reduction. We per-
ormed additional experiments to demonstrate this effect using
PDPE and another cyclic opioid peptide CTOP. The ﬁrst peak at
.48 min  of Fig. 7 had neither a speciﬁc UV proﬁle nor appeared
n the total ion chromatogram (TIC) spectrum during MS  stud-
es. Mass spectrometry proved that the peaks at 8.46 (Fig. 8) and
0.84 min  (Fig. 9) were the cyclic form of the peptide (MW  680) and
he reduced form (MW  682), respectively. Thus, even though the
Fig. 7. HPLC chromatogram of p-Cl-Phe-DPDPE uponFig. 6. HPLC chromatogram of p-Cl-Phe-DPDPE treated with DTT over 30 min.
molecular mass difference is only 2 Da, each form can be identiﬁed
under the LC-MS conditions.
Fraction collection was performed on the peak at 10.84 min,
which is presumably the reduced form of the peptide. Mass spec-
trometry and MS-MS  were performed on the collected fraction. The
fragmentation pattern of this peak is shown in Figure 10.
The MS-MS  spectrum of the peak eluted at 10.84 shows sufﬁ-
cient sequencing information of the linear peptide yielding direct
evidence on the proof of the correct structure for the cyclic peptide.
Thus we have veriﬁed that the later eluting peak in the DTT
treated sample (Fig. 6) is indeed the linear precursor peptide. There-
fore the HPLC method we  used is capable of resolving the cyclic
peptide and its linear precursor peptide.
3.2. DPDPE
Here again, we  have performed a full analysis of the peptide but
only LC-MS data are presented. Although the MS  did not show sufﬁ-
cient fragments to conﬁrm the sequence, the reduced form yielded
all the expected fragments to prove the structure.
DTT was used to perform the reduction of DPDPE. Similar to p-
Cl-Phe-DPDPE, this reaction was also found to be time dependent.
Both the linear and cyclic forms were observable in the HPLC proﬁle
Fig. 11. The corresponding MS  spectra indicated the correct molec-
ular weights 646 and 648 for DPDPE and the reduced linear form,
respectively. Fraction collection was  performed on the linear form
 treatment with DTT under LC-MS conditions.
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Fig. 8. MS  spectrum of DTT-treated sample at retention time 8.46 min.
ed sam
a
r
3
D
cFig. 9. MS  spectrum of DTT-treat
nd analyzed by MS  and MS-MS. The fragmentation pattern of the
educed peptide, the linear form is shown in Fig. 12.
.3. CTOPSimilar to the analyses of the two peptides p-Cl-Phe-DPDPE and
PDPE described above, we have also successfully analyzed the
yclic peptide CTOP (data not presented here).
Fig. 10. MS  fragmentation pattern of the lineple at retention time 10.84 min.
While recognizing the careful planning and the effort expended
to synthesize a well puriﬁed peptide, it is to be noted that analysis
also demands a similar well-planned effort to verify its identity and
integrity. The work presented here clearly demonstrates that.The reagent we  used to reduce the disulﬁde bond in our
experiments, DTT, is quite reliable and we have extended the
same method to analyze other disulﬁde containing cyclic pep-
tides in addition to those mentioned here. However, other
ar form, the reduced p-Cl-Phe-DPDPE.
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Fig. 11. LC and TIC chromatograms of DTT-treated DPDPE.
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pFig. 12. MS fragmentation pattern
ethods have been reported that are equally applicable, including
eagents such as performic acid [20], sodium sulﬁte [21], and
ris(2-carboxyethyl)phosphine (TCEP) [16]. More recent advances
nclude electrochemical methods [22,23].
Of course, the utility of each method depends upon the appli-
ation. Though observing the molecular mass difference of 2 Da
etween the cyclic and linear peptide for small peptides, as
eported here, poses no problems, our methods may  be of limited
se on larger peptides and proteins containing a multitude of disul-
de bonds, because of the broad isotopic distributions observed in
S. In such circumstances, -mercaptoethanol has been shown to
e a useful reagent [24]. Using this reagent, an ampliﬁcation of the
olecular mass difference by 78 Da is obtained for each disulﬁde
ond reduced.
. Conclusions
Reduction via DTT, followed by LC-MS, is a convenient way to
lucidate the structure of cyclic peptides containing disulﬁde bonds
nd to prove the presence and/or absence of any linear precursor
eptide. The MS  fragmentation pattern of the linear form implies
he correct sequence of the cyclic form of the peptide. NMR  methods
uch as 1H-NMR, 1H–1H COSY, and NOESY are also extremely use-
ul tools that can be employed for structural elucidations of cyclic
eptides when the standard methods are not amenable.e linear form, the reduced DPDPE.
The RP-HPLC method reported in this paper for the analysis of
TFA is very efﬁcient, highly reliable, accurate and robust. It can be
easily extended for analyzing other acids, e.g. AA.
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